247 related articles for article (PubMed ID: 30946633)
1. Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon.
Abou Ali B; Salman M; Ghanem KM; Boulos F; Haidar R; Saghieh S; Akel S; Muwakkit SA; El-Solh H; Saab R; Tamim H; Abboud MR
J Glob Oncol; 2019 Apr; 5():1-8. PubMed ID: 30946633
[TBL] [Abstract][Full Text] [Related]
2. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
3. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Choeyprasert W; Natesirinilkul R; Charoenkwan P; Sittipreechacharn S
Asian Pac J Cancer Prev; 2013; 14(2):1101-6. PubMed ID: 23621194
[TBL] [Abstract][Full Text] [Related]
5. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
[TBL] [Abstract][Full Text] [Related]
10. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
11. [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children].
Muñoz Villa A; Ocete G; Aymerich ML; Maldonado S; Otheo E; Calvo M; Amaya J
Med Clin (Barc); 1996 Jun; 107(5):161-4. PubMed ID: 8758673
[TBL] [Abstract][Full Text] [Related]
12. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
13. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
14. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
[TBL] [Abstract][Full Text] [Related]
19. Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
Xu M; Xu S; Yu X
World J Surg Oncol; 2014 Nov; 12():341. PubMed ID: 25391880
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]